SCHEMBL24044992

SCHEMBL24044992

CC(C)N1CCN(c2cccc(Nc3ncc(Cl)c(Nc4ccccc4C(N)=O)n3)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 12/20 0.65
MAPK10 P53779 12/20 0.65
MAPK8 P45983 5/20 0.65
CDC7 O00311 1/20 0.60
DAPK3 O43293 1/20 0.60
JAK2 O60674 1/20 0.60
ROCK2 O75116 1/20 0.60
PRKD3 O94806 1/20 0.60
MAP4K4 O95819 1/20 0.60
PAK4 O96013 1/20 0.60
PIM1 P11309 1/20 0.60
PRKACA P17612 1/20 0.60
CDK2 P24941 1/20 0.60
SYK P43405 1/20 0.60
CSNK1A1 P48729 1/20 0.60
CLK2 P49760 1/20 0.60
GSK3A P49840 1/20 0.60
GSK3B P49841 1/20 0.60
CDK7 P50613 1/20 0.60
CDK9 P50750 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24044993 0.91 MAPK9 (0.77) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL25668157 0.91 EGFR (0.68) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL25668072 0.89 MAPK9 (0.70) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL25668122 0.87 MAPK9 (0.68) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL1203074 0.83 EGFR (0.69) MAPK9MAPK10MAPK8CDK2CDK9
SCHEMBL24044994 0.82 PTK2 (0.79) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL25668162 0.82 EGFR (0.81) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL25483897 0.81 MAP3K7 (0.66) MAPK9MAPK10MAPK8CDK2CDK9
SCHEMBL23200448 0.80 MAPK9 (0.56) MAPK9MAPK10MAPK8CDC7DAPK3
SCHEMBL1203417 0.80 EGFR (0.65) MAPK9MAPK10MAPK8JAK2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230194515-A1 BROAD SPECTRUM KINASE BINDING AGENTS PROMEGA CORPORATION 2023-06-22 US disclosed
US-20230194515-A1 BROAD SPECTRUM KINASE BINDING AGENTS PROMEGA CORPORATION 2023-06-22 US disclosed
US-20210363565-A1 ENHANCEMENT OF KINASE TARGET ENGAGEMENT PROMEGA CORPORATION 2021-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230194515-A1 BROAD SPECTRUM KINASE BINDING AGENTS MAP4K2, MAP3K20, MAP4K1 MAPK9 255/4885MAPK10 241/4885MAPK8 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.